Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

Annals of Hematology

Volumn 94, Issue 3, 2015, Pages 393-397

  Breccia, Massimo ^a   Molica, Matteo ^a   Zacheo, Irene ^a   Serrao, Alessandra ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular; Chronic myeloid leukemia; ESC score; Nilotinib

Indexed keywords

ANTIHYPERTENSIVE AGENT; DASATINIB; IMATINIB; NILOTINIB; PRAVASTATIN; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CORONARY RISK; DYSLIPIDEMIA; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SMOKING; UNSTABLE ANGINA PECTORIS; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CORONARY DISEASE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84922373381     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2231-9     Document Type: Article

References (12)

1. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197–2203
2. Saglio G, Hochhaus A, Hughes TP, Clark RE, Nakamae H, Kim DW et al (2013) ENESTnd update: nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase and the impact of early molecular response and Sokal risk at diagnosis on long-term outcomes. Blood 114:632
3. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533–539
4. le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndhofer S et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347–1348
5. Giles F, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al (2013) Rate of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27:1310–1315
6. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316–1321
7. le Coutre P, Hughes T, Mahon FX, Kim DW, Steegmann JL, Shah NP et al (2013) Peripheral arterial occlusive disease (PAOD) in patients (pts) receiving dasatinib: experience across multiple clinical trials. Blood 122:1489
8. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 19:403–488
9. Saglio G, Larson RA, Hughes TP, Issaragrisil S, Turkina AG, Marin D et al (2010) Efficacy and safety of nilotinib in chronic phase chronic myeloid leukemia patients with type 2 diabetes in the ENESTnd trial. Blood 116:3430
10. Rea D, Gautier JF, Breccia M, Saglio G, Hughes TP, Kantarjian H et al (2012) Incidence of hyperglycemia by 3 years in patients with newly diagnosed of chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib in ENESTnd. Blood 120:1686
11. Hiwase DK, Carne L, Ross D, Grigg A, Hughes TP (2013) Hypercholesterolemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood 122:1503
12. nd generation tyrosine kinase inhibitor nilotinib. Blood 122:4042